{"filing":{"accession_number":"0001193125-26-336497","cik":"0001121404","ticker":"SNYNF","company_name":"Sanofi","form":"6-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d143789d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526336497/d143789d6k.htm"},"events":[{"id":25508,"run_id":23150,"accession_number":"0001193125-26-336497","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces European Commission approval of an expanded indication for MenQuadfi (meningococcal vaccine) to include infants from six weeks of age, a significant regulatory milestone for a marketed product. While not a discrete M\u0026A, financial, or governance event, the regulatory approval of a major label expansion for a vaccine addressing a serious public health threat represents a material operational and commercial development that would affect investor assessment of Sanofi's vaccine portfolio and market opportunities.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":26352,"accession_number":"0001193125-26-336497","item_number":"EX-99.1","item_title":"d143789dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces European Commission approval of an expanded indication for MenQuadfi (meningococcal vaccine) to include infants from six weeks of age, a significant regulatory milestone for a marketed product. While not a discrete M\u0026A, financial, or governance event, the regulatory approval of a major label expansion for a vaccine addressing a serious public health threat represents a material operational and commercial development that would affect investor assessment of Sanofi's vaccine portfolio and market opportunities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:50:13.684021+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26352,"accession_number":"0001193125-26-336497","item_number":"EX-99.1","item_title":"d143789dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces European Commission approval of an expanded indication for MenQuadfi (meningococcal vaccine) to include infants from six weeks of age, a significant regulatory milestone for a marketed product. While not a discrete M\u0026A, financial, or governance event, the regulatory approval of a major label expansion for a vaccine addressing a serious public health threat represents a material operational and commercial development that would affect investor assessment of Sanofi's vaccine portfolio and market opportunities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:50:13.684021+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-08-06"}]}